Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings. - Wikidata - awgldk - TriplyDB

Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings.

Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings.

http://www.wikidata.org/entity/Q36035895

about

PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings Hub and switches: endocannabinoid signalling in midbrain dopamine neurons Role of cues and contexts on drug-seeking behaviour The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys.Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research.Stimulation of nicotine reward and central cholinergic activity in Sprague-Dawley rats exposed perinatally to a fat-rich diet.PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption Prior exposure to THC increases the addictive effects of nicotine in rats.The Reinforcing Effects of Nicotine in Humans and Nonhuman Primates: A Review of Intravenous Self-Administration Evidence and Future Directions for Research.Neuroimmune pathways in alcohol consumption: evidence from behavioral and genetic studies in rodents and humans Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model.Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self-administration and relapse in squirrel monkeys.Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence.Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence.Effects of blockade of α4β2 and α7 nicotinic acetylcholine receptors on cue-induced reinstatement of nicotine-seeking behaviour in rats.Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics Neuroimmune signaling: a key component of alcohol abuse.Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.Hepatic, lipid and genetic factors associated with obesity: crosstalk with alcohol dependence?Fenofibrate Administration Reduces Alcohol and Saccharin Intake in Rats: Possible Effects at Peripheral and Central Levels In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence.Initial Cross-Over Test of a Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers with or Without Schizophrenia.Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential.Lack of effects of simvastatin on smoking cessation in humans: A double-blind, randomized, placebo-controlled clinical study.The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats.Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver Emerging Therapeutic Role of PPAR-α in Cognition and Emotions Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARα agonist) in smokers

P2860

Q21090748-97125ABD-49D7-40D5-AFC1-74F370738E0C Q24623244-BCBA277B-2795-42B3-8FB7-73ADE3CC3E2E Q26825476-71A7B2D5-02B5-485D-8D6C-59FA9AB5B08A Q27325802-3F5416CE-B9FA-41CC-9C67-E7623DE3BD97 Q28283718-87506967-D77C-48BD-9072-AD8F0D791C9D Q30244252-5AF40FE0-9C7D-4FA2-8786-DAFCCCB8EDD0 Q33552906-BA050B52-B4DF-4EAE-9263-0D9EC46FE953 Q34302561-5EC621C1-F82F-4153-B6FD-E1C003B2F172 Q34322263-DEB03FA7-0F6B-4D1E-8473-FE0CA820A6EF Q34462263-918FC4E5-FB3D-4AA9-8329-C08F41B20C49 Q34687635-12B2DFFC-6D93-4C83-8BC6-DCCE993145D2 Q34965339-46B93D91-621C-48D5-9BAD-EF63CA9324D5 Q35019725-C504C04E-BDC1-40F3-ADD5-2CDF7B9DC199 Q36184904-A4ED4824-E246-44A3-A8D9-D6C117E7982A Q36445709-8610CF37-17C8-42C4-B19C-A9721D174A8E Q36727844-787C4FD6-76B0-4E03-8A1C-8598EE0E3A9C Q36939862-A5B2C543-2CEE-45A4-833B-2777400D74AB Q37304747-1A084B89-02A4-403A-9F67-2CAF21B4633F Q37351302-1F75A091-0215-499C-95A2-134C97123513 Q37397620-B5C868DE-C4D4-4E0B-80C4-1C5DFB068076 Q38083975-DFF1D91B-D590-41ED-BBFF-08BE1B291430 Q38686274-0679B236-6EC6-4483-B353-86B26BFD3719 Q38788717-CF4CF219-A742-4DC7-B77C-C5E9F13BA239 Q41010706-4AAA767D-C885-4D84-A879-E86FA8EE9EBA Q45054305-BBF6A0FD-A3FC-416D-AB13-D0B658436C08 Q45074229-1B5ECC2D-177D-45AB-B0EA-8D0C8DC9FE49 Q50094674-FD1CE455-FCAA-4F5A-AB4C-8494DFB17AD6 Q51745545-ED9811D8-54F2-45FB-8C15-3ED5C8B25973 Q52311615-0A984D0B-DD22-4143-A7FB-7E72097DCDA8 Q57072853-B260F8F1-E06C-4B36-902C-D052BB144476 Q57818280-3A1BC294-9E28-4DC6-B608-BB96A8A68BC7 Q58691808-4231E943-9A32-44AD-8204-2D903770A361

P2860

Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings.

http://www.wikidata.org/entity/Q36035895

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Novel use of a lipid-lowering ...... relapse: preclinical findings.

@ast

Novel use of a lipid-lowering ...... relapse: preclinical findings.

@en

type

label

Novel use of a lipid-lowering ...... relapse: preclinical findings.

@ast

Novel use of a lipid-lowering ...... relapse: preclinical findings.

@en

prefLabel

Novel use of a lipid-lowering ...... relapse: preclinical findings.

@ast

Novel use of a lipid-lowering ...... relapse: preclinical findings.

@en

P1433

Q36035895-A8359A6E-0875-41F6-A1F8-0DBF7B94AAE7

P1476

Q36035895-DFACC19A-B6A2-4D4F-89E4-F8BDD8B0EA37

P2093

Q36035895-185FA51B-1ED3-440E-A998-C80A2C06982A

Q36035895-1DF71FD5-065F-4867-81E4-9B78545D30F8

Q36035895-4A63E570-E904-492A-AE57-91D843E2F7DC

Q36035895-67F75CA1-33A6-46C5-BF3A-95858C7F1B10

Q36035895-75102096-7EBE-4458-85D9-D759F7EADDEB

Q36035895-804499BD-8BC0-4855-AB1C-81DF9396FF85

Q36035895-84D8F0C3-DD42-483E-8A00-F5AF155D67E8

Q36035895-A498AC69-A3F0-46C7-BC85-C83672BEFD98

Q36035895-BF7EB6DA-08E2-4E35-A8E3-8CD542A9856F

Q36035895-C1A53820-3179-446A-BC37-26882BA95B1C

P2860

Q36035895-03B2FEA3-862B-4BD7-9228-B4BD5158AABF

Q36035895-0799A631-9DD1-4F71-B28E-D33B026F97DF

Q36035895-0B806E75-C7A2-4AA5-88C1-CBFCBE5BE372

Q36035895-0E68A3B8-C7E4-467F-BFA7-4FE4EB667810

Q36035895-11AE8D91-603F-4433-81E4-09CF79932859

Q36035895-12D90716-6E2C-4A33-88BB-0F0657D10253

Q36035895-1DDD235C-D2A3-484E-9244-170F679A3BFA

Q36035895-228824F8-214E-4BA4-8FAF-81157C394F2B

Q36035895-3B71080A-1889-476A-863C-296280870062

Q36035895-41684FC1-A848-4427-8C76-D241D1E73624

P2888

Q36035895-FFBF2CE8-DAEB-44EB-A532-976D1E8C40C1

P304

Q36035895-6B4E7F6F-DDC1-41E2-9393-F4D0DBB93C30

P31

Q36035895-669929FF-B2F4-4301-BCD1-27D3B2C17BEA

P356

Q36035895-0A2B29E6-31B6-4325-A2D4-A162CC96A296

P407

Q36035895-D2EC0DC2-5DE3-44AA-9B72-AFCBFC0B0A40

P433

Q36035895-28FFBD68-5C50-4399-88F8-53FBF4688C62

P478

Q36035895-03D2C20A-3C48-4810-9A8E-69FCE319AB1B

P50

Q36035895-1236BAA6-E349-4BDE-8CAE-5E94319C3BE1

Q36035895-61765E34-10F1-4FBD-887A-2A5C9DA7D885

Q36035895-C016894C-2FE7-4E59-8158-1FCCF6C06BBA

P577

Q36035895-B0232B6A-1F37-4B6F-9C8C-661F33DA2016

P5875

Q36035895-943AD23F-107B-419A-9019-E3D8AF5B1DC1

P698

Q36035895-92B0A5B7-8DE3-47E1-927D-E8FFD362123B

P932

Q36035895-F773D477-DBD5-47CE-ABEF-86B99E98278C

P356

P1433

Neuropsychopharmacology

P1476

Novel use of a lipid-lowering ...... relapse: preclinical findings

@en

P2093

Chanel Barnes

http://www.w3.org/2001/XMLSchema#string

Godfrey H Redhi

http://www.w3.org/2001/XMLSchema#string

Jordan Adair

http://www.w3.org/2001/XMLSchema#string

Leigh V Panlilio

http://www.w3.org/2001/XMLSchema#string

Mano Aliczki

http://www.w3.org/2001/XMLSchema#string

Marco Pistis

http://www.w3.org/2001/XMLSchema#string

Paola Mascia

http://www.w3.org/2001/XMLSchema#string

Salvatore Lecca

http://www.w3.org/2001/XMLSchema#string

Sevil Yasar

http://www.w3.org/2001/XMLSchema#string

Stephen J Heishman

http://www.w3.org/2001/XMLSchema#string

P2860

Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex.

Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004

Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors

Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs

Neural systems of reinforcement for drug addiction: from actions to habits to compulsion

Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats.

Cue-induced reinstatement of nicotine-seeking behavior in rats: effect of bupropion, persistence over repeated tests, and its dependence on training dose.

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.

Functional brain imaging of tobacco use and dependence.

Peroxisome proliferator-activated receptors-alpha modulate dopamine cell activity through nicotinic receptors.

P2888

P304

1838-1847

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2012.31

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Zuzana Justinova

Antonio Luchicchi

P577

2012-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221978136

http://www.w3.org/2001/XMLSchema#string

P698

22453137

http://www.w3.org/2001/XMLSchema#string

P932

3376316

http://www.w3.org/2001/XMLSchema#string